Management of pregnancy in patients with hypertrophic cardiomyopathy.
The outcome of 54 pregnancies in 23 patients with hypertrophic cardiomyopathy was analysed. No mother or infant died in the perinatal period. Six patients developed dyspnoea requiring treatment with diuretics. Beta-adrenergic blocking drugs were given in 18 pregnancies and three of the infants in this were small for dates and in two fetal bradycardia occurred. The results comfirmed that pregnancy is safe in patients with hypertrophic cardiomyopathy. A flexible approach should be adopted towards administering beta-adrenergic blocking drugs to pregnant women with hypertrophic cardiomyopathy. Many such patients do well without these drugs and can thus avoid the potential hazards--namely, small-for-dates babies and fetal bradycardia--that are associated with them.
D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000188:drug therapy / Q000628:therapy*; D036861:Delivery, Obstetric / Q000379:methods; D003864:Depression, Chemical; D005260:Female; D005318:Fetal Heart / Q000187:drug effects / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D007236:Infant, Small for Gestational Age; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy / Q000628:therapy*; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use
D011433:Propranolol